What smart money is saying about Regeneron Pharmaceuticals Inc.
2 funds in our archive have pitched Regeneron Pharmaceuticals Inc. — most recently Bronte Capital in November 2025.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Get an email when a fund writes about it
Position history
Between Q1 2025 and Q3 2026, 4 fund letters reported a position in Regeneron Pharmaceuticals Inc. — 1 opened or added to the position, 2 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 0 |
| Q2 2026 | 3 | 1 | 2 | 0 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q1 2025 | 0 | 0 | 0 | 1 |
Fund activity · 4 positions · 3 moves
- July 2026
“In July, Amalthea gained 6.54% net whilst the MSCI ACWI (in $A) fell by 1.55%. Performance in the long book was led by Regeneron, with DSM Firmenich, Amazon, Visa and Philip Morris also providing meaningful contributions.”
Regeneron Pharmaceuticals Inc. - June 2026
“We trimmed some of our holding when the market was running hotter on Regeneron’s pipeline prospects earlier this year.”
Regeneron Pharmaceuticals Inc. - TrimmedLongleaf Partners FundJune 2026
“Regeneron – Healthcare company Regeneron was a detractor in the quarter after disappointing trial results for one of its pipeline drugs. When we first invested in the company last year, the keys to the case were continued strength at Dupixent, Eylea stabilization, pipeline success and intelligent capital allocation. Dupixent (over 50% of the value) has outgrown our expectations and Eylea (less than 15% of the value) has stabilized after some initial hiccups. There were three key pipeline readouts coming over the next 18 months when we invested, and Regeneron has now basically gone one out of three, when we thought two out of three was more likely. We trimmed some of our holding when the market was running hotter on Regeneron’s pipeline prospects earlier this year.”
Regeneron Pharmaceuticals Inc. - AddedAugustine Asset Management Global Equity & Fixed Income StrategiesJune 2026
“We initiated during the quarter a new position in Halozyme Therapeutics, a biopharmaceutical company that specializes in drug delivery platforms. We expect the company to scale its royalty-bearing installed base of partnered subcutaneous products and benefit from additional launches. The stock trades at a valuation discount to both industry peers and its own history while having strong quality characteristics and growth potential. We also increased positions in Regeneron, United Therapeutics, Shell, and TotalEnergies following recent weakness.”
Regeneron Pharmaceuticals Inc.
Also mentioned · 2
These funds discuss Regeneron Pharmaceuticals Inc. — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedACATIS Investment ReportJune 2026
“Regeneron Pharmaceuti- cals (-12.5%): This US biotech group came under significant pressure after the skin cancer drug Fianlimab failed to reach the anticipated end points in Phase 3.”
Regeneron Pharmaceuticals Inc. - MentionedACATIS InvestmentJune 2026
“Regeneron Pharmaceuti- cals (-12.5%): This US biotech group came under significant pressure after the skin cancer drug Fianlimab failed to reach the anticipated end points in Phase 3.”
Regeneron Pharmaceuticals Inc.
Fund coverage · 2 theses
- Bronte CapitalNovember 2025
Regeneron leverages proprietary genetic and mouse-model platforms to de-risk and accelerate drug discovery, offering substantial long-term upside from its current below-market valuation.
Read the full thesis - Cambiar Opportunity FundMarch 2025
Regeneron is a high-quality biopharmaceutical operator with a strong R&D foundation, a robust financial position, and a favorable risk/reward opportunity despite a temporary revenue slowdown for its EYLEA product.
Read the full thesis
Read every full thesis on Regeneron Pharmaceuticals Inc.
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→